RecruitingPhase 4NCT06766461
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
Sponsor
Erasmus Medical Center
Enrollment
980 participants
Start Date
Jan 3, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Double dosing of beta-lactam antibiotic for people with sepsis, sepsis - to reduce mortality in the intensive care unit, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDouble dosing of beta-lactam antibiotic
This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06766461
Related Trials
Long-term Assessment of Patients Treated in the ICU for Sepsis
NCT075027941 location
Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation
NCT075301461 location
An Acupuncture Study for People At High Risk for Sepsis
NCT063448191 location
Evaluation of Pediatric eCART Implementation
NCT067718301 location
The Effect of Early Intervention on the Incidence of Posttraumatic Stress Disorder After Intensive Care Hospitalization Due to Sepsis
NCT077077651 location